{
    "nct_id": "NCT01258452",
    "title": "Randomized, Balanced, Single Dose, Cross-Over Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects",
    "status": "COMPLETED",
    "last_update_time": "2015-02-09",
    "description_brief": "To evaluate the effects of a high-calorie high-fat meal on the extent and rate of absorption of CHF 5074 after single oral administration in young healthy male volunteers.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "CHF 5074 (aka CHF5074; also reported as CSP-1103)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational product CHF 5074 is described in the literature as a small-molecule \u03b3-secretase modulator and microglial/inflammation modulator that acts on Alzheimer\u2019s-related pathology (amyloid processing and neuroinflammation). \ue200cite\ue202turn0search0\ue202turn0search3\ue201.",
        "Act: The provided trial title/description is a single-dose, crossover, food-effect pharmacokinetic study of CHF 5074 in healthy young male volunteers \u2014 a Phase 1 PK/safety design consistent with early development of a therapeutic small molecule rather than a biologic or a purely symptomatic cognitive enhancer. \ue200cite\ue202turn0search8\ue201.",
        "Supporting evidence from web search: Preclinical and clinical publications characterize CHF5074 as a \u03b3-secretase modulator that reduces brain A\u03b2 pathology and improves memory in AD models. Clinical Phase 2 work and biomarker studies describe CHF5074 (CSP-1103) as affecting central inflammatory biomarkers (CSF sCD40L, TNF-\u03b1) and showing signals on cognition in subsets, consistent with a disease-targeted mechanism. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search1\ue202turn0search7\ue201.",
        "Reflect: Given CHF5074\u2019s described mechanism (modulation of amyloid generation and microglial/inflammatory pathways) and that it is a small molecule (not a biologic such as an antibody or vaccine), the correct category is \"disease-targeted small molecule.\" There is minor ambiguity because some studies report cognitive benefits, but those are downstream effects of targeting pathology/inflammation rather than purely symptomatic cognitive enhancement; thus the disease-targeted small molecule category is the best fit. \ue200cite\ue202turn0search4\ue202turn0search1\ue201."
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: CHF 5074 (aka CHF5074, CSP\u20111103) is a small\u2011molecule gamma\u2011secretase modulator that has been shown to reduce A\u03b2/plaque burden in animal models (amyloid pathway) and also to modulate microglial activation and reduce inflammatory markers (neuroinflammation). \ue200cite\ue202turn0search3\ue202turn0search0\ue201",
        "Act: The trial description is a single\u2011dose, food\u2011effect PK study in healthy volunteers, but the drug\u2019s mechanism (gamma\u2011secretase modulation + microglial/inflammation modulation) spans two CADRO categories: A) Amyloid beta and F) Inflammation. Because the agent acts on both amyloid processing and inflammatory/microglial pathways, the most specific CADRO classification is R) Multi\u2011target. \ue200cite\ue202turn0search3\ue202turn0search2\ue201",
        "Reflect: This classification reflects published preclinical and clinical characterizations: CHF5074 reduced A\u03b2 and plaques and improved cognition in AD models and has been reported to lower CSF inflammatory biomarkers (e.g., sCD40L, TNF\u2011\u03b1) in human studies, supporting dual amyloid/inflammation activity rather than a purely symptomatic or single\u2011pathway effect. Assigning R) Multi\u2011target is therefore the best fit. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Web search results (supporting evidence summarized): 1) PubMed study showing CHF5074 drives microglial M2 markers and suppresses A\u03b2\u2011induced TNF\u2011\u03b1/IL\u20111\u03b2 in glial cultures (microglial/inflammation effects). \ue200cite\ue202turn0search0\ue201 2) British Journal of Pharmacology report describing CHF5074 as a novel \u03b3\u2011secretase modulator that reduces brain \u03b2\u2011amyloid pathology and improves learning in APP transgenic mice (amyloid pathway). \ue200cite\ue202turn0search3\ue201 3) In vivo/in vitro microglia activation study reporting CHF5074\u2019s anti\u2011neuroinflammatory activity. \ue200cite\ue202turn0search2\ue201 4) ALZFORUM summary of CHF5074 clinical development noting Phase\u20111 PK studies and Phase\u20112 biomarker signals (CSF CD40/TNF\u2011\u03b1) consistent with an anti\u2011inflammatory/amyloid\u2011modulatory profile. \ue200cite\ue202turn0search5\ue201 5) Clinical/press summaries reporting CSF biomarker changes and early cognitive signals in MCI trials. \ue200cite\ue202turn0search4\ue201"
    ]
}